Biotech in ASCO spotlight: Salubris Biotherapeutics updated Phase 1/2 results for JK06, a 5T4-targeted antibody drug conjugate, reporting strong response in squamous NSCLC and a favorable safety profile as the program heads into further monotherapy and combination expansions. Pediatric long COVID follow-up: The PECOS study tracked children and teens after lab-confirmed SARS-CoV-2 infection, finding 20 symptoms more common than in uninfected controls through 12 months, with about two-thirds reporting at least one lingering symptom. Cancer drug pipeline: BioNTech and Bristol Myers Squibb shared interim ROSETTA Lung-02 Phase 2 data for pumitamig (PD-L1xVEGF-A) plus chemotherapy in first-line advanced NSCLC, with high response rates across PD-L1 levels. AI governance for Maryland enterprises: Kiteworks launched an Innovators in AI program at Gartner SRM 2026, offering rapid deployment of AI data access controls and audit capabilities via its Secure MCP Server and ABAC policies. Defense tech in the region: The Marine Corps awarded Oshkosh Defense a $70.6M contract for more ROGUE-Fires carriers to support NMESIS anti-ship missile operations, with production work planned in Virginia and Maryland. Health policy & cannabis: A DOJ reclassification of medical marijuana to Schedule III is expected to unlock some federal tax benefits, but states still face a fragmented federal-state landscape as further DEA steps are debated. Local science-and-safety education: Ocean View Police will run youth programs at Lord Baltimore Elementary, including CPR/Stop the Bleed training and a K-9 operations session.